Clinical Research Directory
Browse clinical research sites, groups, and studies.
Alzheimer's Tau Platform: Regimen A - AADvac1
Sponsor: Paul S. Aisen
Summary
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.
Official title: Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
450
Start Date
2026-06-30
Completion Date
2028-08-31
Last Updated
2026-04-06
Healthy Volunteers
No
Interventions
AADvac1
Subcutaneous injection of AADvac1
Donanemab
Active comparator: intravenous infusion of donanemab